AveXis Inc Stock Is Spiking Again Today -- Here's Why

What happened

Shares of AveXis Inc (NASDAQ: AVXS), a clinical-stage biotech company developing gene therapies, are adding to a tremendous run-up this year with a 16.8% gain as of 11:30 a.m. EDT during Friday's session. Yesterday afternoon, the company included phase 1 trial data that could make this a nervous weekend for Biogen Inc (NASDAQ: BIIB)andIonis Pharmaceuticals Inc (NASDAQ: IONS) investors.

So what

The FDA's last new drug approval of 2016, Spinraza for the treatment of spinal muscular atrophy (SMA), might have some competition sooner than anyone had expected. A commercial launch for the RNA antisense therapy discovered by Ionis and marketed by Biogen is still in its infancy. With a lack of competition and a list price of $750,000 for the first year of treatment (then $375,000 for each year thereafter), it's expected to generate about $2 billion in annual sales at its peak.

Image source: Getty Images.

Of course, market entry of a viable competitor could limit Spinraza's pricing power, and Avexis could have an early clinical-stage candidate capable of applying that pressure. Results from a phase 1 trial released along with its fourth-quarter earnings report yesterday showed that 15 of 15 SMA patients treated with its lead candidate, AVXS-101, remained event-free at 13.6 months. The study didn't include a placebo group for comparison, but historical data suggests a 25% event-free survival rate at this age.

Also encouraging was a 100% event-free survival rate among all nine patients with follow-up data extending out to 20 months. Based on historical data, the expected event-free rate at this age is just 8%.

Now what

Investors will want to keep their eyes open for data from a planned pivotal trial for AVXS-101 designed to support a marketing application in the EU. After meeting with European regulators, it seems the company has been encouraged to run a 30-patient, single-arm trial using historical data as a comparator.Given the results we've seen so far, that trial and subsequent application look like a slam-dunk.

Unlike Spinraza from Biogen and Ionis Pharmaceuticals, AVXS-101 involves a viral vector that crosses the blood-brain barrier and delivers a functional copy of the SMN gene to the patient's own cells.Another stark contrast is a more convenient dosing regimen. While Spinraza requires several doses each year at $125,000 each, AVXS-101 has the potential of becoming a one-time dose regimen.

10 stocks we like better than AveXisWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and AveXis wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 6, 2017.

Cory Renauer has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Biogen and Ionis Pharmaceuticals. The Motley Fool has a disclosure policy.